[The role of atherogenic dyslipidaemia in clinical practice guidelines]

Area of Science:

• Cardiology
• Clinical Lipidology
• Evidence-Based Medicine

Background:

• Atherogenic dyslipidaemia remains underdiagnosed, undertreated, and under-controlled.
• This condition significantly contributes to cardiovascular disease.
• Current clinical practice guidelines show variability in addressing this risk.

Purpose of the Study:

• To evaluate the stance of major clinical guidelines on atherogenic dyslipidaemia.
• To assess how guidelines incorporate lipid parameters in cardiovascular risk assessment and management.
• To identify gaps in guideline recommendations regarding dyslipidaemia.

Main Methods:

• Systematic review of major clinical guidelines published between January 2012 and March 2015.
• Analysis of guidelines from scientific societies and official agencies.
• Extraction of data on high-density lipoprotein (HDL) cholesterol, triglycerides, non-HDL cholesterol, and apolipoprotein (apo) B.

Main Results:

• Most American guidelines, excluding the NLA, do not prioritize HDL cholesterol and triglycerides for cardiovascular prevention.
• Canadian, IAS, and NICE guidelines show more attention to non-HDL cholesterol and ApoB.
• European, Brazilian, and Japanese guidelines mention HDL cholesterol and triglycerides but rely on sub-analysis data.

Conclusions:

• The analyzed clinical guidelines inadequately address the importance of atherogenic dyslipidaemia.
• There is a need for improved and more consistent recommendations for managing dyslipidaemia in cardiovascular prevention.
• Guidelines should more effectively integrate lipid parameters into risk assessment and therapeutic strategies.